Author:
Russmueller Guenter,Seemann Rudolf,Weiss Kathrin,Stadler Victoria,Speiss Manuel,Perisanidis Christos,Fuereder Thorsten,Willinger Birgit,Sulzbacher Irene,Steininger Christoph
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Edwards, B. J. et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. The Lancet. Oncology 9, 1166–1172 (2008).
2. Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg 72, 1938–1956 (2014).
3. Fliefel, R., Troltzsch, M., Kuhnisch, J., Ehrenfeld, M. & Otto, S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg 44, 568–585 (2015).
4. Estilo, C. L. et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. The oncologist 13, 911–920 (2008).
5. Saad, F., Chi, K. & Fleshner, N. The role of bisphosphonates in the management of bone metastases in prostate cancer. The Canadian journal of urology 11, 2376–2382 (2004).
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献